BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

345 related articles for article (PubMed ID: 8841187)

  • 1. An imprinted gene p57KIP2 is mutated in Beckwith-Wiedemann syndrome.
    Hatada I; Ohashi H; Fukushima Y; Kaneko Y; Inoue M; Komoto Y; Okada A; Ohishi S; Nabetani A; Morisaki H; Nakayama M; Niikawa N; Mukai T
    Nat Genet; 1996 Oct; 14(2):171-3. PubMed ID: 8841187
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Genomic imprinting of p57KIP2, a cyclin-dependent kinase inhibitor, in mouse.
    Hatada I; Mukai T
    Nat Genet; 1995 Oct; 11(2):204-6. PubMed ID: 7550351
    [TBL] [Abstract][Full Text] [Related]  

  • 3. p57K1P2 is expressed in Wilms' tumor with LOH of 11p15.5.
    Overall ML; Spencer J; Bakker M; Dziadek M; Smith PJ
    Genes Chromosomes Cancer; 1996 Sep; 17(1):56-9. PubMed ID: 8889507
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Functional analysis of the p57KIP2 gene mutation in Beckwith-Wiedemann syndrome.
    Bhuiyan ZA; Yatsuki H; Sasaguri T; Joh K; Soejima H; Zhu X; Hatada I; Morisaki H; Morisaki T; Mukai T
    Hum Genet; 1999 Mar; 104(3):205-10. PubMed ID: 10323243
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Genomic imprinting of human p57KIP2 and its reduced expression in Wilms' tumors.
    Hatada I; Inazawa J; Abe T; Nakayama M; Kaneko Y; Jinno Y; Niikawa N; Ohashi H; Fukushima Y; Iida K; Yutani C; Takahashi S; Chiba Y; Ohishi S; Mukai T
    Hum Mol Genet; 1996 Jun; 5(6):783-8. PubMed ID: 8776593
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Selective maternal-allele loss in human lung cancers of the maternally expressed p57KIP2 gene at 11p15.5.
    Kondo M; Matsuoka S; Uchida K; Osada H; Nagatake M; Takagi K; Harper JW; Takahashi T; Elledge SJ; Takahashi T
    Oncogene; 1996 Mar; 12(6):1365-8. PubMed ID: 8649840
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Imprinting status of 11p15 genes in Beckwith-Wiedemann syndrome patients with CDKN1C mutations.
    Li M; Squire J; Shuman C; Fei YL; Atkin J; Pauli R; Smith A; Nishikawa J; Chitayat D; Weksberg R
    Genomics; 2001 Jun; 74(3):370-6. PubMed ID: 11414765
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Low frequency of p57KIP2 mutation in Beckwith-Wiedemann syndrome.
    Lee MP; DeBaun M; Randhawa G; Reichard BA; Elledge SJ; Feinberg AP
    Am J Hum Genet; 1997 Aug; 61(2):304-9. PubMed ID: 9311734
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Beckwith-Wiedemann syndrome: multiple molecular mechanisms.
    Enklaar T; Zabel BU; Prawitt D
    Expert Rev Mol Med; 2006 Jul; 8(17):1-19. PubMed ID: 16842655
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Human p57(KIP2) defines a new imprinted domain on chromosome 11p but is not a tumour suppressor gene in Wilms tumour.
    Taniguchi T; Okamoto K; Reeve AE
    Oncogene; 1997 Mar; 14(10):1201-6. PubMed ID: 9121769
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CDKN1C expression in Beckwith-Wiedemann syndrome patients with allele imbalance.
    Algar EM; Deeble GJ; Smith PJ
    J Med Genet; 1999 Jul; 36(7):524-31. PubMed ID: 10424812
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cyclin-dependent kinase inhibitor p57KIP2 in soft tissue sarcomas and Wilms'tumors.
    Orlow I; Iavarone A; Crider-Miller SJ; Bonilla F; Latres E; Lee MH; Gerald WL; Massagué J; Weissman BE; Cordón-Cardó C
    Cancer Res; 1996 Mar; 56(6):1219-21. PubMed ID: 8640801
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Overgrowth syndromes and genomic imprinting: from mouse to man.
    Li M; Squire JA; Weksberg R
    Clin Genet; 1998 Mar; 53(3):165-70. PubMed ID: 9630066
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Coding mutations in p57KIP2 are present in some cases of Beckwith-Wiedemann syndrome but are rare or absent in Wilms tumors.
    O'Keefe D; Dao D; Zhao L; Sanderson R; Warburton D; Weiss L; Anyane-Yeboa K; Tycko B
    Am J Hum Genet; 1997 Aug; 61(2):295-303. PubMed ID: 9311733
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New p57KIP2 mutations in Beckwith-Wiedemann syndrome.
    Hatada I; Nabetani A; Morisaki H; Xin Z; Ohishi S; Tonoki H; Niikawa N; Inoue M; Komoto Y; Okada A; Steichen E; Ohashi H; Fukushima Y; Nakayama M; Mukai T
    Hum Genet; 1997 Oct; 100(5-6):681-3. PubMed ID: 9341892
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular biology of Beckwith-Wiedemann syndrome.
    Weksberg R; Squire JA
    Med Pediatr Oncol; 1996 Nov; 27(5):462-9. PubMed ID: 8827075
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Analysis of CDKN1C in Beckwith Wiedemann syndrome.
    Algar E; Brickell S; Deeble G; Amor D; Smith P
    Hum Mutat; 2000; 15(6):497-508. PubMed ID: 10862080
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Acute lymphocytic leukaemia in a child with Beckwith-Wiedemann syndrome harbouring a CDKN1C mutation.
    Abadie C; Bernard F; Netchine I; Sanlaville D; Roque A; Rossignol S; Coupier I
    Eur J Med Genet; 2010; 53(6):400-3. PubMed ID: 20826236
    [TBL] [Abstract][Full Text] [Related]  

  • 19. p57KIP2 targeted disruption and Beckwith-Wiedemann syndrome: is the inhibitor just a contributor?
    Swanger WJ; Roberts JM
    Bioessays; 1997 Oct; 19(10):839-42. PubMed ID: 9363677
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular subtypes and phenotypic expression of Beckwith-Wiedemann syndrome.
    Cooper WN; Luharia A; Evans GA; Raza H; Haire AC; Grundy R; Bowdin SC; Riccio A; Sebastio G; Bliek J; Schofield PN; Reik W; Macdonald F; Maher ER
    Eur J Hum Genet; 2005 Sep; 13(9):1025-32. PubMed ID: 15999116
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.